Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Dendritic cell-based vaccination in solid cancer.

A Stift1, J Friedl, P Dubsky

  • 1Department of Surgery, University of Vienna Medical School, Vienna, Austria. a.stift@akh-wien.ac.at

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|December 31, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial.

ESMO open·2026
Same author

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

The impact of analysis methodology details on invasive breast cancer-free survival in randomized clinical trials.

ESMO open·2025
Same author

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).

ESMO open·2025
Same author

Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same journal

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Dendritic cell (DC) vaccination using tumor lysate is safe for advanced cancer patients lacking defined antigens. This immunotherapy can induce immune responses and achieve clinical benefits, even in patients with advanced disease.

Area of Science:

  • Immunology
  • Oncology
  • Cell Therapy

Background:

  • Dendritic cell (DC)-based immunotherapy is a promising cancer treatment.
  • Current DC therapies often require known tumor antigens, limiting application in many advanced cancers.
  • This study explores DC vaccination in patients with advanced disease lacking defined tumor antigens.

Purpose of the Study:

  • To evaluate the safety and efficacy of autologous tumor lysate-pulsed dendritic cell vaccination in patients with advanced cancers.
  • To assess the induction of tumor-specific immune responses.
  • To determine clinical outcomes in patients with advanced, antigen-undefined malignancies.

Main Methods:

  • Twenty patients with stage IV pancreatic, hepatocellular, cholangiocellular, and medullary thyroid carcinoma were enrolled.

Related Experiment Videos

  • Autologous monocytes were cultured into immature dendritic cells (DCs), pulsed with tumor lysate, and matured.
  • Mature DCs were administered into lymph nodes, with adjuvant interleukin-2 support.

    • Main Results:

    • DC vaccination was well-tolerated with no signs of autoimmunity.
    • Delayed-type hypersensitivity was induced in 18 patients, and tumor marker responses in eight.
    • Objective tumor changes were observed in seven patients, demonstrating clinical activity.

    Conclusions:

    • Autologous tumor-pulsed DC vaccination is safe and feasible for advanced cancers.
    • This approach can elicit tumor-specific cellular immunity and achieve clinical responses.
    • DC immunotherapy offers a viable option for patients with advanced disease lacking defined tumor antigens.